ReviewHealth science reports2026
Hypertension as a Predictor of Ovarian Cancer Risk: A Systematic Review and Meta-Analysis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Ovarian cancer is a primary contributor to cancer-related deaths among women and holds a position among the most common gynecological malignancies worldwide. While hypertension has been identified as a potential risk factor for various cancers, its association with ovarian cancer remains inconclusive. This systematic review and meta-analysis synthesized data from observational studies to provide light on the association between hypertension and the risk of ovarian cancer. Methods: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and secured registration with the PROSPERO under the identifier CRD42025636649. A systematic literature search of PubMed, Embase, and Web of Science was conducted to identify observational studies published through December 10, 2024. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using the Results: Out of 2686 articles identified, 11 studies with a total of 2,523,751 participants met the inclusion criteria. There was a risk ratio (RR) of 1.06 (95% CI, 0.96-1.20) for ovarian cancer in patients with hypertension, and considerable heterogeneity was noted ( Conclusion: There is no statistically significant association between high blood pressure and the risk of ovarian cancer, according to this meta-analysis. To confirm these results, additional research utilizing larger participant groups and robust study designs is essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.